Id |
Subject |
Object |
Predicate |
Lexical cue |
T103 |
0-4 |
Sentence |
denotes |
3.1. |
T104 |
5-64 |
Sentence |
denotes |
Performance of Eight SARS-CoV-2 IgG or Total Antibody Tests |
T105 |
65-213 |
Sentence |
denotes |
Thirty-seven samples taken from patients with a PCR-confirmed SARS-CoV-2 infection were analyzed with eight SARS-CoV-2 IgG or total antibody assays. |
T106 |
214-357 |
Sentence |
denotes |
Samples #1, #7, and #9 were taken nine days before to four days after PCR and were all found to be free of SARS-CoV-2 antibodies by the assays. |
T107 |
358-470 |
Sentence |
denotes |
These samples were not considered for calculation of the sensitivity but demonstrated seroconversion (Figure 1). |
T108 |
471-571 |
Sentence |
denotes |
Out of the remaining 34 samples, only one serum (#20; Figure 1), which was obtained from patient no. |
T109 |
572-681 |
Sentence |
denotes |
12 ten days after a positive RT-PCR, tested negative for SARS-CoV-2 IgG/total antibodies in the eight assays. |
T110 |
682-730 |
Sentence |
denotes |
However, this sample exhibited a PRNT 1:10–1:20. |
T111 |
731-796 |
Sentence |
denotes |
All other samples were reactive in at least one assay (Figure 1). |
T112 |
797-912 |
Sentence |
denotes |
Twenty (76.9%) patients developed virus-neutralizing antibodies, as shown by a PRNT >1:10 (Figure 1 and Figure S1). |
T113 |
913-1054 |
Sentence |
denotes |
With respect to the SARS-CoV-2 PCR (reference 1) or the PRNT results (reference 2), assay sensitivities ranged from 80.8% to 96.3% (Table 1). |
T114 |
1055-1155 |
Sentence |
denotes |
Specificity was calculated using 100 archived samples that should not contain SARS-CoV-2 antibodies. |
T115 |
1156-1212 |
Sentence |
denotes |
A total of ten sera were reactive in one or more assays. |
T116 |
1213-1288 |
Sentence |
denotes |
None contained SARS-CoV-2 neutralizing antibodies (Figure 2 and Figure S1). |
T117 |
1289-1434 |
Sentence |
denotes |
The residual 90 stored samples were not tested in the PRNT, as they were found to be free of SARS-CoV-2 IgG/total antibodies in all eight assays. |
T118 |
1435-1540 |
Sentence |
denotes |
Thus, assay specificities ranged from 96.0% to 100%, and accuracies varied from 93.7% to 99.2% (Table 1). |
T119 |
1541-1695 |
Sentence |
denotes |
Twelve routine samples obtained from individuals who were interested in their SARS-CoV-2 antibody status were re-evaluated by all eight assays (Figure 3). |
T120 |
1696-1777 |
Sentence |
denotes |
Six of them—including three family members of the SARS-CoV-2-infected patient no. |
T121 |
1778-1876 |
Sentence |
denotes |
14 (Figure 1)—were classified SARS-CoV-2 IgG/total antibody-positive by the majority of the tests. |
T122 |
1877-1935 |
Sentence |
denotes |
Isolated reactivity was observed in three sera (Figure 3). |
T123 |
1936-2117 |
Sentence |
denotes |
Twenty-four (92.3%) of the 26 SARS-CoV-2 infected patients were reactive in one or both versions of the IgG recomLine assay; the test results differed only in three sera (Figure 1). |
T124 |
2118-2352 |
Sentence |
denotes |
One out of the ten archived sera that were reactive in at least one of the SARS-CoV-2 IgG/total antibody tests was also classified as SARS-CoV-2 IgG-positive by the prototype immunoblot (v1) but was negative in the improved version 2. |
T125 |
2353-2603 |
Sentence |
denotes |
The underlying sample #7 was collected in the winter 2018/2019 and was found to be reactive for SARS-CoV-2 IgG/total antibodies by the Mikrogen (S/CO 1.33), Roche (S/CO 3.46), and Viramed (N antigen 125 ViraChip® Units) assays in parallel (Figure 2). |
T126 |
2604-2780 |
Sentence |
denotes |
The twelve routine samples were analyzed by both versions of the blot (v1: nine samples and v2: all samples), and results of the immunoassays were largely confirmed (Figure 3). |